Indiva Crecimiento futuro

Future controles de criterios 2/6

Se prevé que los ingresos deIndiva aumenten en 12% al año. Se prevé que el BPA de grow sea de 105.3% al año.

Información clave

n/a

Tasa de crecimiento de los beneficios

105.3%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	63.4%
Tasa de crecimiento de los ingresos	11.6%
Rentabilidad financiera futura	55.9%
Cobertura de analistas	Low
Última actualización	04 Jan 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Indiva Limited (CVE:NDVA) Stock Catapults 33% Though Its Price And Business Still Lag The Industry

Sep 29

Previsiones de crecimiento de beneficios e ingresos

TSXV:NDVA - Estimaciones futuras de los analistas y datos financieros pasados (CAD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2025	46	N/A	3	1	1
12/31/2024	43	N/A	3	2	1
12/31/2023	37	N/A	3	1	1
9/30/2023	36	-7	0	1	N/A
6/30/2023	34	-9	0	1	N/A
3/31/2023	35	-10	1	2	N/A
12/31/2022	34	-11	0	2	N/A
9/30/2022	34	-12	-10	-9	N/A
6/30/2022	34	-16	-12	-10	N/A
3/31/2022	35	-15	-16	-14	N/A
12/31/2021	32	-15	-20	-18	N/A
9/30/2021	30	-18	-9	-7	N/A
6/30/2021	25	-15	-14	-12	N/A
3/31/2021	19	-16	-11	-9	N/A
12/31/2020	15	-15	-9	-7	N/A
9/30/2020	8	-11	-11	-11	N/A
6/30/2020	5	-10	-10	-7	N/A
3/31/2020	3	-10	-13	-8	N/A
12/31/2019	1	-11	-22	-10	N/A
9/30/2019	1	-11	-23	-9	N/A
6/30/2019	0	-10	-23	-9	N/A
3/31/2019	0	-10	-23	-11	N/A
12/31/2018	0	-9	-14	-10	N/A
9/30/2018	N/A	-7	-10	-8	N/A
6/30/2018	N/A	-6	-8	-7	N/A
3/31/2018	N/A	-5	-4	-3	N/A
12/31/2017	N/A	-3	-5	-2	N/A
9/30/2017	N/A	-2	-6	-2	N/A
6/30/2017	N/A	-2	N/A	-1	N/A
3/31/2017	N/A	-1	N/A	-2	N/A
12/31/2016	N/A	-1	N/A	-1	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de NDVA es superior a la tasa de ahorro (1.9%).

Beneficios frente mercado: Datos insuficientes para determinar si se prevé que los beneficios de NDVA crezcan más deprisa que el mercado Canadian

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de NDVA crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: NDVASe prevé que los ingresos de la empresa (12% al año) crezcan más deprisa que los del mercado Canadian (6.8% al año).

Ingresos de alto crecimiento: NDVASe prevé que los ingresos de la empresa (12% al año) crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Futura rentabilidad financiera (ROE): NDVASe prevé que la Rentabilidad de los fondos propios de la empresa sea muy elevada dentro de 3 años (78%).

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Indiva Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target increased by 15% to CA$0.15

Indiva Limited Provides Revenue Guidance for Fourth Quarter of 2023

Indiva Limited Provides Revenue Guidance for the Second Quarter of 2023

Price target decreased to CA$0.50

Indiva Limited Provides Revenue Guidance for the Second Half and Full Year of 2022

Indiva Limited Provides Revenue Guidance for the Second Quarter of 2022

Recent updates

New major risk - Market cap size

Insufficient new directors

Indiva Limited announced that it expects to receive CAD 4.312 million in funding

Indiva Limited announced that it expects to receive CAD 4 million in funding

Price target increased by 15% to CA$0.15

Indiva Limited Provides Revenue Guidance for Fourth Quarter of 2023

Third quarter 2023 earnings released: CA$0.005 loss per share (vs CA$0.018 loss in 3Q 2022)

Indiva Limited to Report Q3, 2023 Results on Nov 21, 2023

Indiva Limited (CVE:NDVA) Stock Catapults 33% Though Its Price And Business Still Lag The Industry

Is Indiva (CVE:NDVA) Using Debt In A Risky Way?

Second quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.017 loss in 2Q 2022)

Indiva Limited to Report Q2, 2023 Results on Aug 29, 2023

Indiva Limited Launches No Future Gummies and Vapes

New minor risk - Shareholder dilution

New major risk - Share price stability

Indiva Limited announced that it expects to receive CAD 2.155617 million in funding from Canopy Growth Corporation

Indiva Limited Provides Revenue Guidance for the Second Quarter of 2023

Indiva Limited, Annual General Meeting, Jul 18, 2023

Indiva Limited to Report Q1, 2023 Results on May 16, 2023

Is Indiva (CVE:NDVA) A Risky Investment?

Full year 2022 earnings: EPS and revenues miss analyst expectations

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to CA$0.50

Indiva Limited to Report Q3, 2022 Results on Nov 22, 2022

Indiva Limited Provides Revenue Guidance for the Second Half and Full Year of 2022

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Indiva Limited to Report Q2, 2022 Results on Aug 16, 2022

Indiva Limited Provides Revenue Guidance for the Second Quarter of 2022

Consensus estimates of losses per share improve by 62%

Indiva Limited Provides Revenue Guidance for the Second Quarter of 2022

Indiva Limited to Report Q1, 2022 Results on May 19, 2022

Price target decreased to CA$0.60

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Indiva Limited Provides Net Revenue Guidance for the First Quarter of 2022

Indiva Limited, Annual General Meeting, Jun 23, 2022

Indiva Limited to Report Fiscal Year 2021 Results on Apr 26, 2022

Is Indiva (CVE:NDVA) Using Too Much Debt?

Indiva Limited Launches New Cannabis Edible Designed for MicroDosing

Indiva Launches New Cannabis Edible Formulated for Night-Time Use

Third quarter 2021 earnings released: CA$0.047 loss per share (vs CA$0.035 loss in 3Q 2020)

Would Indiva (CVE:NDVA) Be Better Off With Less Debt?

Second quarter 2021 earnings released: CA$0.01 loss per share (vs CA$0.029 loss in 2Q 2020)

Indiva Limited Provides Revenue Guidance for the Second Half of 2021

First quarter 2021 earnings released: CA$0.025 loss per share (vs CA$0.029 loss in 1Q 2020)

Full year 2020 earnings released: CA$0.16 loss per share (vs CA$0.14 loss in FY 2019)

Indiva Limited to Introduce Two New Bhang Chocolate Flavours Nationally in Second Quarter of 2021

Indiva Limited Ships Wana Quick Gummies

Indiva Limited Appoints Russell Wilson to the Board of Directors

Indiva Limited announced that it has received CAD 11 million in funding from Sundial Growers Inc.

Indiva Announces Extension to License Agreement with Wana Brands Inc

Indiva Limited announced that it expects to receive CAD 11 million in funding from Sundial Growers Inc.

New 90-day high: CA$0.49

New 90-day high: CA$0.28

Independent Director recently bought CA$65k worth of stock

Indiva Limited Promotes Rob Carse to Chief Operating Officer

Price target raised to CA$0.63

Analysts increase revenue estimates to CA$14.9m

Would Indiva (CVE:NDVA) Be Better Off With Less Debt?

Third quarter 2020 earnings released: CA$0.035 loss per share

New 90-day low: CA$0.21

New 90-day low: CA$0.23

Indiva Secures Agreement with Medical Cannabis by Shoppers Inc

Indiva Ships Wana Sour Gummies to Alberta, Saskatchewan, and Yukon Territory

Indiva Ships Wana™ Sour Gummies to British Columbia

Analysts update estimates

Price target lowered to CA$0.55

First half earnings released

Indiva Limited announced that it has received CAD 5.179499 million in funding from Marotta Investments Limited, Prairie Merchant Corporation, ATB Capital Markets Inc.

New 90-day low - CA$0.27